Literature DB >> 20399706

"Cognitive" visual acuity estimation based on the event-related potential P300 component.

Sven P Heinrich1, David Marhöfer2, Michael Bach2.   

Abstract

OBJECTIVE: An objective assessment of sensory and sensuo-cognitive function, based on physiological signals rather than on the behavioral response of a patient, is often advisable, albeit challenging. Evoked potentials are frequently used as an objective measure, but usually fail to detect defects beyond primary sensory areas, including those of psychogenic origin. Here we assess whether the event-related P300 component may be used to measure "cognitive" visual acuity.
METHODS: A visual oddball paradigm was used to elicit P300 responses in subjects with normal or artificially blurred vision. Probe stimuli consisted of infrequently presented gratings with spatial frequencies in the range of 2.2-16.2 cycles per degree, which could be either target or non-target stimuli depending on their orientation. Frequent stimuli were homogeneously grey fields.
RESULTS: Without blur, rare stimuli of all spatial frequencies produced reliable P300 responses. Blur abolished the P300 to fine gratings consistently in 10 of 11 subjects. The drop in P300 amplitude was steep, rather than gradual, between visible and invisible gratings.
CONCLUSION: The P300 is sensitive to identify the resolution threshold and thus may serve as a tool for estimating acuity in cases of visual impairments. SIGNIFICANCE: The study presents a tool for the objective assessment of acuity in cases of higher-level visual impairments. The concept can most likely be extended to other sensory modalities. 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20399706     DOI: 10.1016/j.clinph.2010.03.030

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  9 in total

1.  Objective measurement of visual resolution using the P300 to self-facial images.

Authors:  David J Marhöfer; Michael Bach; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2015-05-15       Impact factor: 2.379

2.  P300-based acuity estimation in imitated amblyopia.

Authors:  Marvin L Beusterien; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2017-11-13       Impact factor: 2.379

3.  Visual evoked potential-based acuity assessment: overestimation in amblyopia.

Authors:  Yaroslava Wenner; Sven P Heinrich; Christina Beisse; Antje Fuchs; Michael Bach
Journal:  Doc Ophthalmol       Date:  2014-03-13       Impact factor: 2.379

4.  Faces are more attractive than motion: evidence from two simultaneous oddball paradigms.

Authors:  David J Marhöfer; Michael Bach; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2014-03-21       Impact factor: 2.379

5.  Normal sensory and absent cognitive electrophysiological responses in functional visual loss following chemical eye burn.

Authors:  Nada Jiraskova; Miroslav Kuba; Jan Kremlacek; Pavel Rozsival
Journal:  Doc Ophthalmol       Date:  2011-06-07       Impact factor: 2.379

Review 6.  VEP estimation of visual acuity: a systematic review.

Authors:  Ruth Hamilton; Michael Bach; Sven P Heinrich; Michael B Hoffmann; J Vernon Odom; Daphne L McCulloch; Dorothy A Thompson
Journal:  Doc Ophthalmol       Date:  2020-06-02       Impact factor: 2.379

7.  One of the most well-established age-related changes in neural activity disappears after controlling for visual acuity.

Authors:  Fábio H G Porto; Erich S Tusch; Anne M Fox; Brittany R Alperin; Phillip J Holcomb; Kirk R Daffner
Journal:  Neuroimage       Date:  2016-01-26       Impact factor: 6.556

8.  Real-time feature extraction of P300 component using adaptive nonlinear principal component analysis.

Authors:  Arjon Turnip; Keum-Shik Hong; Myung-Yung Jeong
Journal:  Biomed Eng Online       Date:  2011-09-23       Impact factor: 2.819

9.  The "speed" of acuity in scotopic vs. photopic vision.

Authors:  Sven P Heinrich; Torben Blechenberg; Christoph Reichel; Michael Bach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-15       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.